Skip to Content

BromSite Approval History

BromSite (bromfenac) is a low dose nonsteroidal anti-inflammatory drug (NSAID) ophthalmic solution for the treatment of inflammation and prevention of pain in patients undergoing cataract surgery.

Development History and FDA Approval Process for BromSite

Apr  9, 2016Approval Sun Pharma Receives FDA Approval For BromSite (bromfenac ophthalmic solution)
Aug 17, 2015InSite Vision Announces FDA Acceptance of NDA Filing for BromSite (0.075% bromfenac)
Jun 11, 2015InSite Vision Announces Completion of the NDA Submission for BromSite

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.